.Nature Medication, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Viewpoint requires addition of patients along with MASLD and also size of liver outcomes in cardio-- kidney-- metabolic trials, when records advise mechanistically conceivable benefits as well as professional safety-- and also outlines points to consider for trial concept and also regulatory commendation.